Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study

Lignende værker

• A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis
  af: Akizawa, Tadao, et al.
  Udgivet: (2020)
• Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
  af: Akizawa, Tadao, et al.
  Udgivet: (2021)
• Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
  af: Akizawa, Tadao, et al.
  Udgivet: (2019)
• Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies
  af: Akizawa, Tadao, et al.
  Udgivet: (2020)
• Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
  af: Hirai, Keiji, et al.
  Udgivet: (2021)